Thrive With Type 1 Diabetes 2026 Study
This study is looking at whether a 12-week behavioral program can help adults with type 1 diabetes improve their sleep and blood sugar levels. You might be eligible if you are 31 to 75 years old, have had type 1 diabetes for at least a year, and have some sleep issues. The study will compare two approaches: one is a cognitive behavioral intervention called TranS-C that focuses on sleep habits, and the other is an enhanced usual care approach. Researchers will measure your overall sleep health and your HbA1C (a measure of average blood sugar over time) at the beginning and after 14 weeks to see if these interventions are helpful. The current status of this study is unclear, and it plans to enroll 48 participants.
- Study design
- This is an interventional study comparing two behavioral approaches. It plans to enroll 48 participants.
- What's involved
- You would participate in a 12-week intervention, which includes telehealth appointments. Your sleep health and HbA1C will be measured at the start and after 14 weeks.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your sleep health and HbA1C will be measured at 14 weeks from baseline.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Thrive With Type 1 Diabetes 2026
At a glance
Conditions
Where it's being run
2 sites across 1 statesStudy leadership
- Stephanie Griggs, PhD, RN, FAAN · PRINCIPAL_INVESTIGATOR · Emory University
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Multidimensional sleep health composite scoreBaseline and post-intervention (14 weeks from baseline)
The multidimensional sleep health composite score assesses six domains: regularity, satisfaction, alertness, timing, efficiency, and duration. Sleep regularity, timing, efficiency, and duration will be measured using a non-dominant wrist-worn research-grade actigraph (Ametris CentrePoint Insight Watch) worn 24/7 during the monitoring period. Sleep satisfaction will be assessed using the global score of the 19-item Pittsburgh Sleep Quality Index (PSQI; range 0-21; scores \<5 coded as 1, indicating good sleep). Alertness will be assessed using the Epworth Sleepiness Scale (ESS; range 0-24; scores \<8 coded as 1, indicating good daytime alertness). Each component will be scored according to predefined criteria and summed to create a composite score ranging from 0 to 6, with higher scores indicating better overall sleep health over the 1-week monitoring period at each time point. The composite score (unitless) will be assessed at baseline and post-intervention.
- Glycated hemoglobin (HbA1C)Baseline and post-intervention (14 weeks from baseline)
HbA1C will be measured by the FDA-approved A1C Now Self-Check. HbA1C reflects the average blood glucose level over the preceding approximately 2-3 months and will be reported as a percentage (%). Changes in glycemia will be assessed by comparing HbA1C values measured at baseline and post intervention. Units = percent (%).